Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide)

Reproductive BioMedicine Online

Volumn 3, Issue 1, 2001, Pages 14-18

  Felberbaum, R E ^a   Kupker W ^a   Krapp, M ^a   Gehl, B ^a   Ludwig, M ^a   Diedrich, K ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

depot preparation; fibroids; GnRH antagonists; intermediate; short term treatment

Indexed keywords

CETRORELIX; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE; SEX HORMONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CANCER HORMONE THERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL OUTCOME; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONE INHIBITION; HUMAN; HYSTEROGRAPHY; LAPAROSCOPIC SURGERY; LAPAROTOMY; LUTEINIZING HORMONE BLOOD LEVEL; MEDICATION COMPLIANCE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYOMECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE TREATMENT; PROGESTERONE BLOOD LEVEL; SHORT COURSE THERAPY; UTERUS MYOMA;

EID: 85006282703     PISSN: 14726483     EISSN: 14726491     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61957-8     Document Type: Article

References (22)

1. Brosens, I, Johannisson, E, Dal Cin, P, et al. Analysis of the karyotype and desoxyribonucleic acid content of uterine myomas in premenopausal, menopausal and gonadotropin-releasing hormone agonist treated females. Fertility and Sterility 66 (1996), 376–379.
2. Buchi, K, Keller, PJ, Estrogen receptors in normal and myomatous human uteri. Gynecologic and Obstetric Investigation 11 (1980), 59–60.
3. Coddington, CC, Collins, RL, Shawker, TH, et al. Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. Fertility and Sterility 45 (1986), 624–629.
4. Cohen, J, Elia, D, Relevance of an LHRH agonist to the treatment of uterine fibromyomas. Vickery, BH, Lunenfeld, B, (eds.) Benign and malignant tumours, 1990, Kluwer, Dordrecht-Boston-London, 33–44.
5. Creighton, S, Bourne, TH, Lawton, FG, et al. Use of transvaginal ultrasonography with color Doppler imaging to determine an appropriate treatment regimen for uterine fibroids with a GnRH agonist before surgery: a preliminary study. Ultrasound in Obstetrics and Gynecology 4 (1994), 494–498.
6. Eldar-Geva, T, Healy, DL, Other medical management of uterine fibroids. Baillierés Clinical Obstetrics and Gynaecology 12 (1998), 269–288.
7. Felberbaum, RE, Germer, U, Ludwig, M, et al. Treatment of uterine fibroids with a slow release formulation of the gonadotrophin releasing hormone antagonist cetrorelix. Human Reproduction 13 (1998), 1660–1668.
8. Filicori, M, Hall, DA, Loughlin, JS, et al. A conservative approach to the management of uterine leiomyomata: pituitary desensitization by a luteinizing hormone-releasing hormone analogue. American Journal of Obstetrics and Gynecology, 147, 1983, 72.
9. Friedman, AJ, Barbieri, RL, Benacerraf, BR, Schiff, I, Treatment of leiomyomata with intranasla or subcutanous leuprolide, a gonadotropin-releasing hormone agonist. Fertility and Sterility 48 (1987), 560–564.
10. Gonzalez-Barcena, D, Banuelos Alvarez, R, Pere Ochoa, et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist cetrorelix. Human Reproduction 12 (1997), 2028–2035.
11. Kawaguchi, K, Fujii, S, Konishi, I, et al. Immunohistochemical analysis of estrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Archives 419 (1991), 309–315.
12. Kettel, LM, Murphy, AA, Morales, AJ, et al. Rapid regression of uterine leiomyomas in response to daily administration of gonadotrophin-releasing hormone antagonist. Fertility and Sterility 60 (1993), 642–645.
13. Kurjak, A, Kupesic-Urek, S, Miric, D, The assessment of benign uterine tumor vascularization by transvaginal color Doppler. Ultrasound in Medicine and Biology 18 (1992), 645–649.
14. Lemay, A, Maheux, R, Faure, N, et al. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis. Fertility and Sterility 41 (1984), 863–871.
15. Olivennes, F, Fanchin, R, Bouchard, P, et al. The single or dual administration of the gonadotrophin-releasing hormone antagonist cetrorelix in an in vitro fertilization–embryo transfer programme. Fertility and Sterility 62 (1994), 468–476.
16. Olivennes, F, Fanchin, R, Bouchard, P, et al. Scheduled administration of gonadotrophin releasing hormone antagonist (cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Human Reproduction 10 (1995), 1382–1386.
17. Olivennes, F, Belaisch-Allart, J, Emperaire, JC, et al. Prospective, randomised, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertility and Sterility 73 (2000), 314–320.
18. Pandis, N, Heim, S, Willen, H, et al. Histologic-cytogenetic correlations in uterine leiomyomas. International. Journal of Gynecological Cancer 1 (1991), 163–168.
19. Pollow, K, Geilfuss, J, Boquoi, E, Pollow, B, Estrogen and progesterone binding proteins in normal human myometrium and leiomyoma tissue. Journal of Clinical Chemistry and Clinical Biochemistry 16 (1978), 503–511.
20. Reissmann, T, Felberbaum, R, Diedrich, K, et al. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Human Reproduction 10 (1995), 1974–1981.
21. West, CP, Lumsden, MA, Lawson, S, et al. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutanous depot. Fertility and Sterility 48 (1987), 45–51.
22. Wilson, EA, Yang, F, Rees, ED, Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue. Obstetrics and Gynecology 55 (1980), 20–24.